Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Fallopian tube neoplasms | D005185 | — | — | — | 1 | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 5 | — | — | — | — | 5 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Essential thrombocythemia | D013920 | — | D47.3 | 1 | — | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Thrombocytosis | D013922 | HP_0001894 | D75.83 | 1 | — | — | — | — | 1 |
Drug common name | Tasisulam |
INN | tasisulam |
Description | Tasisulam is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Small molecule |
Drug class | antineoplastics, apoptosis inducing sulfonamide |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl |
PDB | — |
CAS-ID | 519055-62-0 |
RxCUI | — |
ChEMBL ID | CHEMBL2110587 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11941 |
UNII ID | 1YC4W9MSLJ (ChemIDplus, GSRS) |